Pharsight

Stendra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6656935 METUCHEN PHARMS Aromatic nitrogen-containing 6-membered cyclic compounds
Apr, 2025

(1 year, 6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7501409 METUCHEN PHARMS Preparations for oral administration
May, 2023

(4 months ago)

Stendra is owned by Metuchen Pharms.

Stendra contains Avanafil.

Stendra has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Stendra are:

  • US7501409

Stendra was authorised for market use on 27 April, 2012.

Stendra is available in tablet;oral dosage forms.

Stendra can be used as treatment of erectile dysfunction.

The generics of Stendra are possible to be released after 18 October, 2025.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Oct 18, 2025

Drugs and Companies using AVANAFIL ingredient

Market Authorisation Date: 27 April, 2012

Treatment: Treatment of erectile dysfunction

Dosage: TABLET;ORAL

How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage

STENDRA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic